Microbot Medical Inc. (NASDAQ: MBOT), a US-based medical device company that develops, manufactures and distributes the Liberty Endovascular Robotic System, announced on Wednesday that the Japanese Patent Office has granted its first patent in Japan, covering the core Liberty technology.

The patent protects a compact robotic device designed for use in the remote delivery and manipulation of guidewires and catheters. Over the past 90 days, Microbot Medical has also secured patents in the United States, China and Israel.

On September 8, 2025, the company received marketing clearance for the Liberty System from the US Food and Drug Administration. It has since accelerated commercial launch plans, targeting an estimated 2.5 million peripheral endovascular procedures performed annually in the United States.

Microbot Medical said its global intellectual property strategy is designed to protect and monetise its technology as it evaluates expansion into markets that traditionally accept FDA-cleared devices, however, its initial focus is on the US market.